![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, June 02, 2020 9:46:46 AM
BY MT Newswires
05/26/2020
(MT Newswires) -- Meridian Bioscience ( VIVO ) said that it will provide its SARS-CoV-2 antigens and related reagents for the production of tens of millions of COVID-19 antibody tests per month.
Those antigens and related reagents are part of assays granted Emergency Use Authorization by the US Food and Drug Administration, the company said.
Price: 16.10, Change: +1.27, Percent Change: +8.56
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM